Langlois-Thérien Timothé, Shamy Michel, Dewar Brian, Ramsay Tim, Lun Ronda, Blacquiere Dylan, Fahed Robert, Dowlatshahi Dar, Stotts Grant, Ducroux Célina
Division of Neurology, Department of Medicine, University of Ottawa, Ottawa, ON, Canada.
Ottawa Hospital Research Institute, Ottawa, ON, Canada.
Neurohospitalist. 2025 May 2:19418744251338601. doi: 10.1177/19418744251338601.
BACKGROUND: Monitoring stroke patients in critical-care units for 24 h after thrombolysis or endovascular thrombectomy is considered standard of care in current guidelines but is not evidence-based. Due to the COVID-19 pandemic, our center adopted a targeted protocol in April 2021 with 24-h critical-care monitoring no longer being guaranteed for stroke patients receiving reperfusion treatment. We aim to compare the incidence and timing of complications during the year under the targeted approach compared to prior years when the standard of care was followed. METHODS: We conducted a single-center retrospective cohort study. We analyzed data from stroke patients treated with thrombolysis and/or endovascular thrombectomy in 2019 (pre-COVID-19, standard of care), 2020 (during COVID-19, standard of care) and 2021 (during COVID-19, targeted protocol). Data extracted included demographics, the nature and timing of complications within the first 24 h, and the unit at the time of complication. RESULTS: Three hundred forty-nine patients were included in our study: 78 patients in 2019, 115 patients in 2020, and 156 patients in 2021. In 2021, 32% of patients experienced at least 1 complication within the first 24 h compared to 34% in 2020 and 27% in 2019. In 2021, 33% of patients admitted to critical-care units had a complication compared to 29% in non-critical care units. In 2021, 70% of complications had occurred by hour 8 compared to 49% in 2020 and 29% in 2019. CONCLUSIONS: The incidence and timing of complications did not significantly worsen under the targeted approach compared to prior years and were not associated with hospital location.
背景:在当前指南中,对接受溶栓或血管内取栓治疗的中风患者在重症监护病房进行24小时监测被视为标准治疗方案,但并非基于证据。由于新冠疫情,我们中心在2021年4月采用了一种有针对性的方案,接受再灌注治疗的中风患者不再保证进行24小时重症监护监测。我们旨在比较在采用有针对性方法的这一年与遵循标准治疗方案的前几年相比并发症的发生率和发生时间。 方法:我们进行了一项单中心回顾性队列研究。我们分析了2019年(新冠疫情前,标准治疗方案)、2020年(新冠疫情期间,标准治疗方案)和2021年(新冠疫情期间,有针对性方案)接受溶栓和/或血管内取栓治疗的中风患者的数据。提取的数据包括人口统计学信息、最初24小时内并发症的性质和发生时间,以及并发症发生时所在的科室。 结果:我们的研究纳入了349例患者:2019年78例,2020年115例,2021年156例。2021年,32%的患者在最初24小时内至少发生1种并发症,2020年为34%,2019年为27%。2021年,入住重症监护病房的患者中有33%发生并发症,非重症监护病房为29%。2021年,70%的并发症在第8小时前发生,2020年为49%,2019年为29%。 结论:与前几年相比,在有针对性的方法下并发症的发生率和发生时间没有显著恶化,且与医院位置无关。
Neurohospitalist. 2025-5-2
Cochrane Database Syst Rev. 2025-4-24
Neurocrit Care. 2020-10
Neurocrit Care. 2020-10
Stroke. 2018-11
J Clin Med Res. 2018-3